Literature DB >> 22687682

Severe enophthalmos and lagophthalmos secondary to HIV-associated lipoatrophy.

Jennifer Edith De Niro1, Rona Z Silkiss.   

Abstract

HIV-associated lipoatrophy has been closely linked to the use of the thymidine nucleoside reverse-transcriptase inhibitors stavudine and zidovudine. The lipoatrophy can have severe psychological effects and is associated with increased risk of metabolic disorders and cardiovascular disease. The authors present a case of a 45-year-old HIV-positive man who presented with severe bilateral enophthalmos (recession of the eyes) and lagophthamos (inability to fully close the eyes) from orbital fat atrophy. He had taken zidovudine for 8 years and stavudine for 13 years. Cessation of the causative drugs usually does not result in noticeable improvement of the lipoatrophy. Placement of bilateral orbital floor implants decreased our patient's orbital volume and substantially improved his eyelid function and cosmetic appearance.

Entities:  

Mesh:

Year:  2011        PMID: 22687682      PMCID: PMC4545109          DOI: 10.1136/bcr.06.2011.4376

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

Authors:  S A Mallal; M John; C B Moore; I R James; E J McKinnon
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

2.  Bilateral enophthalmos as a manifestation of HIV infection-related lipoatrophy.

Authors:  N Merchante; J A García-García; S Vergara; J A Mira; J Macías; J A Pineda
Journal:  HIV Med       Date:  2004-11       Impact factor: 3.180

3.  Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

Authors:  Emma Hammond; Elizabeth McKinnon; David Nolan
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

4.  Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Authors:  Carl Grunfeld; Michael Saag; Joseph Cofrancesco; Cora Elizabeth Lewis; Richard Kronmal; Steven Heymsfield; Phyllis C Tien; Peter Bacchetti; Michael Shlipak; Rebecca Scherzer
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

5.  Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.

Authors:  Rona Z Silkiss; Han Lee; Vincent L Gills Ray
Journal:  Arch Ophthalmol       Date:  2009-03

6.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

7.  The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.

Authors:  David Wohl; Rebecca Scherzer; Steven Heymsfield; Michael Simberkoff; Stephen Sidney; Peter Bacchetti; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2008-05-01       Impact factor: 3.731

8.  Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.

Authors:  Giuseppe Vittorio L De Socio; Giustino Parruti; Tiziana Quirino; Elena Ricci; Giuseppe Schillaci; Beatrice Adriani; Patrizia Marconi; Marzia Franzetti; Canio Martinelli; Francesca Vichi; Giovanni Penco; Claudio Sfara; Giordano Madeddu; Paolo Bonfanti
Journal:  J Infect       Date:  2008-04-24       Impact factor: 6.072

9.  Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy.

Authors:  H M Crane; C Grunfeld; R D Harrington; K K Uldall; P S Ciechanowski; M M Kitahata
Journal:  HIV Med       Date:  2008-08-27       Impact factor: 3.180

10.  Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Authors:  Stephane De Wit; Caroline A Sabin; Rainer Weber; Signe Westring Worm; Peter Reiss; Charles Cazanave; Wafaa El-Sadr; Antonella d'Arminio Monforte; Eric Fontas; Matthew G Law; Nina Friis-Møller; Andrew Phillips
Journal:  Diabetes Care       Date:  2008-02-11       Impact factor: 17.152

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.